Cumberland Pharmaceuticals Inc.

NASDAQ:CPIX

Drug Manufacturers - Specialty & Generic

Healthcare
$6.57 -1.07%

-$0.06 today

Market cap
$98.52M
Beta
0.10
P/E (TTM)
-11.5
EPS (TTM)
-$0.48
52W Low $1.85High $6.61

Volume 0.16M

Average 0.97M

CPIX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Cumberland Pharmaceuticals Inc.NASDAQ: CPIX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $1.56M rose 18.6% year over year, ahead of the -11.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 17.7% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Depreciation & amortization amounted to 11.9% of revenue in FY2025, down 4.1 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.6% holds above the trailing-twelve-month pace of -11.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.56M+17.7% QoQ
Last fiscal yearDec 2025
$5.29M-12.5% YoY
LTMMar 2026
$5.25M-11.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.6%——
1 year-12.5%——
3-year CAGR-0.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
5.29M USD
Year-over-year change
-12.5%
4-year CAGR
+3.5%

Depreciation & Amortization vs competitors

How CPIX compares with its peers on the latest reported figures

  • CPIX's LTM Mar 2026 depreciation & amortization of $5.25M is the 2nd largest of the 4 companies compared; the peer median is $16.56K.
  • Its year-over-year change of -11.5% is the 2nd highest of 4, against a peer median of -24.4%.
  • Depreciation & amortization amounts to 12.5% of revenue for CPIX, versus a peer median of 13.9%.
CPIX Competitors Peer median
Depreciation & Amortization for CPIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$7.3M -7.9%-8.2%27.5%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$5.25M -11.5%-0.3%12.5%
LTRNLantern Pharma Inc.LTM Mar 2026$16.56K -84.4%+19.7%—
DYAIDyadic International, Inc.LTM Mar 2026$12.35K -24.4%—0.4%
Peer median (excluding CPIX) $16.56K-24.4%+5.7%13.9%

Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(3.6M)(5.65M)(6.28M)(6.48M)(2.86M)
Depreciation & Amortization4.61M5.33M5.77M6.04M5.29M
Deferred Income Tax(192.82K)0000
Stock-Based Compensation741.87K447.5K365.04K301.9K408.32K
Change in Working Capital8.18M10.97M4.63M1.29M2.16M
Accounts Receivables5.5M(6.12M)3.4M(1.94M)(5.24M)
Inventory4.82M1.38M(23.14K)2.41M2.24M
Accounts Payables(757.59K)15.07M3.72M(991.36K)6.71M
Other Working Capital(1.38M)644.92K(2.47M)1.82M(1.55M)
Other Non-Cash Items(3.39M)(2.64M)1.6M(1.77M)(59.95K)
Operating Cash Flow6.34M8.45M6.09M(612.19K)4.93M
Capital Expenditures(354.46K)(2.07M)(453.05K)(179.71K)(97.9K)
Acquisitions (Net)0(13.5M)000
Purchases of Investments(200K)000(4.48M)
Sales of Investments00000
Other Investing Activities52.57K1.9M347.36K237.56K(47K)
Investing Cash Flow(501.89K)(13.67M)(105.7K)57.84K(4.71M)
Debt Repayment01.2M(3.42M)2.49M(10.04M)
Common Stock Issued00005.27M
Common Stock Repurchased(1.39M)(1.05M)(740.53K)(579.05K)(263.48K)
Dividends Paid00000
Other Financing Activities(2.17M)(2.21M)(3.27M)(1.72M)(1.71M)
Financing Cash Flow(3.55M)(2.06M)(7.42M)196.9K(6.75M)
Effect of Forex Changes00000
Net Change in Cash2.29M(7.28M)(1.44M)(357.44K)(6.52M)
Free Cash Flow5.99M6.38M5.64M(791.9K)4.83M

Cumberland Pharmaceuticals Inc.

NASDAQ:CPIX

Intrinsic Alpha fair value

Locked

Current Price

$6.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.